MARK2 anticorps (N-Term)

N° du produit ABIN2742780

Cet anticorps anti-MARK2 est un anticorps Lapin Polyclonal détectant MARK2 dans WB, IHC, IF, IHC (p) et ICC. Adapté pour Humain, Souris et Rat.

Aperçu rapide pour MARK2 anticorps (N-Term) (ABIN2742780)

Antigène: MARK2 (MAP/microtubule Affinity-Regulating Kinase 2 (MARK2))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MARK2 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC)

Détail du produit anti-MARK2 anticorps

Épitope: N-Term

Specificité: Recognizes endogenous levels of MARK2 protein.

Purification: Immunoaffinity purified

Immunogène: KLH-conjugated synthetic peptide encompassing a sequence within the N-terminal region of human MARK2.

Type of Immunogen: Synthetic peptide

Information d'application

Indications d'application: Approved: ICC (1:100 - 1:500), IF, IHC, IHC-P (1:100 - 1:200), WB (1:500 - 1:1000)

Commentaires:

Target Species of Antibody: Human

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: PBS,  pH 7.3, 0.01 % sodium azide, 30 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Aliquot to avoid freeze/thaw cycles.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot to avoid freeze/thaw cycles.

Détails sur MARK2

Antigène: MARK2 (MAP/microtubule Affinity-Regulating Kinase 2 (MARK2))

Autre désignation: MARK2

Sujet: Name/Gene ID: MARK2
Subfamily: MARK
Family: Protein Kinase

Synonyms: MARK2, ELKL motif kinase 1, EMK-1, ELKL motif kinase, EMK1, PAR-1, PAR1 homolog, Par1b, Par-1b, Ser/Thr protein kinase PAR-1B, Emk, PAR1 homolog b

ID gène: 2011

Pathways: SARS-CoV-2 Protein Interactome, Phosphorylation & l'infection par le SRAS-CoV-2